All In Biotech

Drugs by condition

Drugs approved for acute myeloid leukemia

Brand-name prescription drugs and biologics whose FDA label lists acute myeloid leukemia as an approved use. Matched on the label phrases: "acute myeloid leukemia".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

22

Still marketed, NDA or BLA

Drug classes

9

Novel drugs

14

New molecular entities and new biologics

In development

28

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for acute myeloid leukemia.

  • Filkri (Filgrastim-Laha) · Accord Biopharma Inc. Jan 15, 2026
  • Komzifti (Ziftomenib) · Kura NovelBreakthrough therapyPriority reviewOrphanNov 13, 2025
  • Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025
  • Revuforj (Revumenib Citrate) · Syndax NovelBreakthrough therapyPriority reviewOrphanNov 15, 2024
  • Nypozi (Filgrastim-Txid) · Tanvex Biopharma USA INC OrphanJun 28, 2024

All approved drugs for acute myeloid leukemia, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 2 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Leukocyte Growth Factor (6)

  • Leukine Sargramostim · Berlex Labs · 1991
  • Neupogen Filgrastim · Amgen · 1991
  • Filkri Filgrastim-Laha · Accord Biopharma Inc. · 2026
  • Nypozi Filgrastim-Txid · Tanvex Biopharma USA INC · 2024
  • Nivestym Filgrastim-Aafi · Hospira INC · 2018
  • Zarxio Filgrastim-Sndz · Sandoz INC · 2015

Nucleoside Metabolic Inhibitor (3)

  • Inqovi Cedazuridine, Decitabine · Taiho Oncology · 2020
  • Onureg Azacitidine · Bristol · 2020
  • Vyxeos Cytarabine, Daunorubicin · Jazz Pharms Therap · 2017

Menin Inhibitor (1)

Hedgehog Pathway Inhibitor (1)

  • Daurismo Glasdegib Maleate · Pfizer · 2018

Isocitrate Dehydrogenase 1 Inhibitor (1)

  • Tibsovo Ivosidenib · Servier · 2018

Kinase Inhibitor (1)

  • Rydapt Midostaurin · Novartis · 2017

BCL-2 Inhibitor (1)

CD33-directed Immunoconjugate (1)

  • Mylotarg Gemtuzumab Ozogamicin · Wyeth Pharms INC · 2017

Class not listed in FDA's data (7)

  • Grafapex Treosulfan · Medexus · 2025
  • Revuforj Revumenib Citrate · Syndax · 2024
  • Vanflyta Quizartinib Dihydrochloride · Daiichi Sankyo INC · 2023
  • Rezlidhia Olutasidenib · Rigel Pharms · 2022
  • Xospata Gilteritinib Fumarate · Astellas · 2018
  • Idhifa Enasidenib Mesylate · Bristol Myers Squibb · 2017
  • Idarubicin Hydrochloride Idarubicin Hydrochloride · Pfizer · 1997

Drugs in development for acute myeloid leukemia

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • BL-M11D1Phase 32 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes

  • ClifutinibHEC73543Phase 32 trials

    Sunshine Lake Pharma Co., Ltd. · Leukemia, Acute Myeloid (AML), Acute Myeloid Leukemia, Adult

  • CrenolanibPhase 32 trials

    Arog Pharmaceuticals, Inc. · Newly Diagnosed FLT3 Mutated AML, Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

  • GM-CSFPhase 32 trials

    Y-mAbs Therapeutics · Neuroblastoma, Acute Myeloid Leukemia

  • HMPL-306Phase 32 trials

    Hutchmed · Acute Myeloid Leukemia, Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation

  • ASTX030cedazuridine + azacitidinePhase 31 trial

    Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm

  • XY0206Phase 31 trial

    Shijiazhuang Yiling Pharmaceutical Co. Ltd · Acute Myeloid Leukemia With FLT3/ITD Mutation

  • RVU120SEL120Phase 23 trials

    Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome

  • bexmarilimabFP-1305Phase 22 trials

    Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia

  • IMGN632Phase 22 trials

    AbbVie · Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia

  • AB8939Phase 21 trial

    AB Science · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia

  • ABD-3001DIMATEPhase 21 trial

    Advanced BioDesign · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes

  • ARD103Phase 21 trial

    ARCE Therapeutics, Inc. · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)

  • BP1001Phase 21 trial

    Bio-Path Holdings, Inc. · Acute Myeloid Leukemia (AML)

  • CFI-400945Phase 21 trial

    Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

  • CLN-049Phase 21 trial

    Cullinan Therapeutics Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML

  • CTX-712Phase 21 trial

    Chordia Therapeutics, Inc. · Acute Myeloid Leukemia, Myelodysplastic Syndromes

  • Debio 1562MPhase 21 trial

    Debiopharm International SA · Acute Myeloid Leukemia

  • EP0042Phase 21 trial

    Ellipses Pharma · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

More on acute myeloid leukemia: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.